American Society of Hirudotherapy

Life without blood: Molecular and functional analysis of hirudins and hirudin-like factors of the Asian non-hematophagous leech Whitmania pigra

Müller C, Wang Z, Hamann M, Sponholz D, Hildebrandt JP (2022) · Journal of Thrombosis and Haemostasis

Preclinical / molecular study: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Model / material
molecular identification, cloning, recombinant expression in E. coli, and functional thrombin-inhibition assays of putative hirudin sequences from Whitmania pigra transcriptome data; cross-checked with Hirudo nipponia transcriptomes (University of Greifswald, Germany)
Method
Recombinant Whitmania pigra hirudin-family protein expression and functional characterization
Main result
First identification and functional characterization of multiple hirudin-encoding sequences in Whitmania pigra; some recombinant proteins demonstrated thrombin-inhibitory activity, others were hirudin-like factors (HLFs) with weak or absent thrombin inhibition; exon/intron gene structures elucidated; some W. pigra hirudin coding sequences also detected in Hirudo nipponia transcriptomes

Key Findings

  • First demonstration of functional hirudins in a non-hematophagous leech
  • Whitmania pigra expresses both true hirudins (thrombin inhibitors) and hirudin-like factors (weak/no thrombin inhibition)
  • Some W. pigra hirudin coding sequences shared with Hirudo nipponia
  • Exon/intron gene structure resolved
  • Challenges traditional view that anti-coagulant pharmacology requires hematophagous evolution

Limitations

  • Recombinant proteins from E. coli may differ from native molecules
  • No in-vivo or mammalian pharmacokinetic data
  • Limited population sampling
  • No quantitative comparison to H. medicinalis hirudin potency on standardized assay
  • W. pigra is not the K040187 device leech

Clinical Implications

Müller 2022 fundamentally expanded the understanding of leech hirudin pharmacology by showing that even non-hematophagous Whitmania pigra harbors functional thrombin inhibitors. For ASH, the paper supports the broader narrative that leech pharmacology is species-diverse — important context for explaining to regulators, clinicians, and researchers why Chinese-medicine Whitmania pigra use does not directly translate to K040187 US clinical practice. Pure scientific relevance only.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.